WARNING: “Buffett Indicator” flashing for first time in 50 years

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW

Ozan Pamir Biography and Net Worth

CFO of 180 Life Sciences

Ozan has played a key role in the formation of 180 Life Sciences as the CFO of two of the subsidiaries since late 2018 and oversaw the merger of 180 Therapeutics, Katexco and Cannbiorex, which now form 180 Life Sciences. He was instrumental in completing the company’s NASDAQ listing and managed majority of the funding rounds for the company.

Throughout his career, Ozan has specialized in helping companies in defining their corporate strategy, and executing corporate transactions such as M&As and IPOs. He brings a wealth of knowledge and experience to the 180 Life Sciences team as a former investment banker with in-depth capital markets expertise. Ozan was previously VP of Investment Banking at a leading Canadian independent investment bank, where he co-founded the origination department which focused on small and mid-cap financing and advisory mandates. In this role he advised private and public companies on M&A deals and was the lead banker on more than 30 financings, raising approximately $400 million.

After his investment banking career, Ozan became a venture capitalist with a hands on approach, where he gained valuable experience as CFO and/or board member to early stage biotech companies. Ozan was the CFO of Enosi Life Sciences and the CFO and a board member of Unify Pharmaceuticals, both pre-clinical companies focused on autoimmune diseases.

Ozan holds an Economics and Finance degree from McGill University and is a CFA Charterholder.

What is Ozan Pamir's net worth?: The estimated net worth of Ozan Pamir is at least $5,407.02 as of November 22nd, 2024. Mr. Pamir owns 2,907 shares of 180 Life Sciences stock worth more than $5,407 as of December 21st. This net worth estimate does not reflect any other investments that Mr. Pamir may own. Additionally, Mr. Pamir receives a salary of $410,240.00 as CFO at 180 Life Sciences. Learn More about Ozan Pamir's net worth.
How old is Ozan Pamir?: Mr. Pamir is currently 32 years old. There are 3 older executives and no younger executives at 180 Life Sciences. The oldest executive at 180 Life Sciences is Dr. James N. Woody M.D., Ph.D., CEO & Director, who is 82 years old. Learn More on Ozan Pamir's age.
What is Ozan Pamir's salary?: As the CFO of 180 Life Sciences Corp., Mr. Pamir earns $410,240.00 per year. The highest earning executive at 180 Life Sciences is Dr. James N. Woody M.D., Ph.D., CEO & Director, who commands a salary of $617,770.00 per year. Learn More on Ozan Pamir's salary.
How do I contact Ozan Pamir?: The corporate mailing address for Mr. Pamir and other 180 Life Sciences executives is 30 PARK PLACE SUITE 45E, NEW YORK NY, 10007. 180 Life Sciences can also be reached via phone at (650) 507-0669 and via email at [email protected]. Learn More on Ozan Pamir's contact information.
Has Ozan Pamir been buying or selling shares of 180 Life Sciences?: Ozan Pamir has not been actively trading shares of 180 Life Sciences in the last ninety days. Most recently, on Thursday, May 18th, Ozan Pamir bought 271 shares of 180 Life Sciences stock. The stock was acquired at an average cost of $19.19 per share, with a total value of $5,200.49. Following the completion of the transaction, the chief financial officer now directly owns 472 shares of the company's stock, valued at $9,057.68. Learn More on Ozan Pamir's trading history.
Who are 180 Life Sciences' active insiders?: 180 Life Sciences' insider roster includes Donald McGovern, Jr. (Director), Ozan Pamir (CFO), Quan Vu (COO), and James Woody (CEO). Learn More on 180 Life Sciences' active insiders.

Ozan Pamir Insider Trading History at 180 Life Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/18/2023	Buy	271	$19.19	$5,200.49	472
12/10/2021	Buy	10	$1,470.60	$14,706.00

Ozan Pamir Buying and Selling Activity at 180 Life Sciences

180 Life Sciences Company Overview

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

Today's Range

Now: $1.86

$1.86

$2.02

50 Day Range

MA: $2.88

$1.36

$6.47

2 Week Range

Now: $1.86

$1.16

$17.75

Volume

52,501 shs

Average Volume

732,560 shs

Market Capitalization

$1.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.12

WARNING: “Buffett Indicator” flashing for first time in 50 years

From Behind the Markets | Ad